title: Hemolytic anemia during 24 weeks of ribavirin and interferon-alpha2b combination therapy does not influence the cardiac function of patients with viral hepatitis C.
authors.forename: Shuichi
authors.initials: S
authors.lastname: Sato
authors.forename: Kouichiro
authors.initials: K
authors.lastname: Furuta
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Miyake
authors.forename: Tomoko
authors.initials: T
authors.lastname: Mishiro
authors.forename: Naruaki
authors.initials: N
authors.lastname: Kohge
authors.forename: Shuji
authors.initials: S
authors.lastname: Akagi
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Uchida
authors.forename: M A K
authors.initials: MA
authors.lastname: Rumi
authors.forename: Shunji
authors.initials: S
authors.lastname: Ishihara
authors.forename: Kyouichi
authors.initials: K
authors.lastname: Adachi
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Kinoshita
mesh_terms: D000743:Anemia, Hemolytic / Q000139:chemically induced*; D004359:Drug Therapy, Combination; D005260:Female; D006454:Hemoglobins / Q000032:analysis / Q000187:drug effects; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood* / Q000187:drug effects; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D006454:Hemoglobins; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D020097:Natriuretic Peptide, Brain; D012254:Ribavirin